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Abstract 
Background: Human lipodystrophies are uncommon disorders, with important clinical consequences, which are 
often undiagnosed. The Barraquer–Simons syndrome is a form of partial symmetric lipodystrophy of unknown etiol-
ogy, characterized by the loss of subcutaneous adipose tissue, limited to upper part of the body. Insulin resistance and 
metabolic complications are less common than with other lipodystrophy subtypes. Patients usually have decreased 
serum complement-component 3 levels, associated with complement activation by the alternative pathway, which 
may indicate the presence of renal involvement.
Case presentation: The authors report a case of a 31-year-old woman with progressive loss of subcutaneous fat, 
limited to the face, neck and thorax. She presented no severe metabolic complications, neither signs of insulin resist-
ance. Laboratory tests revealed mild dyslipidemia, and low serum levels of complement-component 3. Clinical and 
biochemical characteristics were consistent with the diagnosis of Barraquer–Simons syndrome.
Conclusion: The present case illustrates the importance of recognizing the clinical features of this lipodystrophic 
syndrome, which may present potentially severe consequences and psychological distress. A brief overview is made, 
addressing the clinical signs of the disease, its course, and how to manage it.
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Background
Human lipodystrophies are a group of acquired or inher-
ited disorders which are characterized by selective fat 
loss, ranging from partial to generalized [1, 2]. Lipod-
ystrophies are usually tightly linked with severe meta-
bolic complications, which highlight the significance of 
adipose tissue as an active endocrine organ [3]. Insulin 
resistance, diabetes mellitus, dyslipidemia, hypertension 
and hepatic steatosis are often seen in affected patients 
[1, 2]. The severity of metabolic disease usually corre-
lates with the extent of fat loss, suggesting that insulin 
resistance could result from the absence of adipose tissue 
and the consequent leptin deficiency [4, 5]. More than a 
century ago, Mitchell [6], Barraquer [7], and Simons [8] 
described the first lipodystrophic disorder, known as 
lipodystrophia progressiva, or Barraquer–Simons syn-
drome, which is now called ‘acquired partial lipodys-
trophy’ (APL). Approximately 250 patients have been 
described in the literature [9], the majority being of Euro-
pean descent [10]. Females are three to four times more 
likely to be affected than men [11]. Fat loss usually starts 
during childhood or adolescence, and may follow an 
acute viral infection such as measles [12, 13]. Barraquer–
Simons syndrome is mainly characterized by the loss of 
subcutaneous tissue, limited to upper part of the body, 
with the face, neck, arms, thorax, and upper abdomen 
being affected in a cephalocaudal manner (cephalotho-
racic lipodystrophy). In contrast, the adipose stores of the 
gluteal regions and lower extremities tend to be either 
preserved or are increased [11]. Unlike others types of 
lipodystrophy, insulin resistance and its related meta-
bolic complications appear to be less frequent (diabetes 
10 %, hypertriglyceridemia 30 %) and are less severe [13]. 
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One third of patients presented membranoproliferative 
glomerulonephritis and associated signs of activation of 
alternative complement pathway—the reduction of cir-
culating concentrations of complement-component 3 
(C3), and the presence of the C3-nephritic factor [14, 15]. 
The authors describe the clinical case of a female patient 




A 31-one-year old Caucasian woman was referred to the 
endocrinology department for a facial lipodystrophy. She 
was the second child of non-consanguineous, healthy par-
ents. The neonatal period and her psychomotor develop-
ment were unremarkable. She had chickenpox during her 
childhood, and later mumps at the age of fifteen. Her first 
menstruation was when she was 12 years old, and she had 
had regular menstrual cycles ever since. At puberty, she 
noted that her subcutaneous adipose facial tissue gradu-
ally began to decrease (Fig. 1). No abnormality in her past 
medical history existed, and she had never used any drug 
that could cause lipodystrophy. There was no family his-
tory of the same condition and furthermore, she did not 
report any symptoms. A physical examination revealed 
facial lipoatrophy, with loss of buccal fat pads and promi-
nent zygomatic arches. She presented bilateral breast 
hypoplasia. The subcutaneous fat was preserved in other 
anatomic regions, particularly in the lower abdomen and 
thighs (Fig.  2). She presented normal thyroid palpation. 
Hepatosplenomegaly, umbilical hernia, acanthosis nigri-
cans, clitorimegaly, hirsutism or acromegalic features were 
all absent. Ophthalmic and other systemic examinations 
were unremarkable, including her neurological status and 
deafness was excluded. Laboratory tests, including a com-
plete blood count, biochemical parameters (with renal and 
liver function tests), urine analysis with urinary albumin 
excretion, insulin-like growth factor-1 (IGF-1), and sexual 
and thyroid function tests revealed no abnormalities. Her 
fasting glucose (70, 82  mg/dL) and insulin (2.7  mU/mL), 
A1c (5.2  %) and oral glucose tolerance test (2  h plasma 
glucose 96  mg/dL) presented normal values. There was 
a discrete elevation of LDL-cholesterol (139 mg/dL), and 
reduced HDL-cholesterol (54 mg/dL), with normal triglyc-
erides level. The C3 levels were low, detected as <18 mg/
dL (normal: 83–177  mg/dL). The patient presented no 
renal disease, nor more severe metabolic disorders up until 
our last observation. She underwent surgical correction of 
facial lipoatrophy, with good aesthetic results.
Discussion
The overall clinical and biochemical features of our 
patient led us to consider Barraquer–Simons syndrome 
as being the main diagnosis. The abnormal fat repartition 
was in conformity with the essential criterion proposed 
by Misra et al. [12]: with gradual symmetrical subcutane-
ous fat loss from the face, neck, upper extremities, thorax 
and abdomen, preserving the lower extremities. Some 
supportive criteria were also met, namely: onset during 
adolescence, the absence of a family history of lipodystro-
phy, and low serum levels of C3. The lack of C3 allows 
for a clear distinction between this syndrome and other 
forms of lipodystrophy. The C3-nephritic factor induces 
lysis of adipocytes expressing factor D (adipsin)—a ser-
ine protease enzyme—and the overt expression of factor 
D by numerous tissues, which produces the characteris-
tic fat loss pattern [3, 16]. Some patients may progress to 
present drusen—small accumulations of hyaline bodies 
underneath the retina [17]. Such as in this present case, 
metabolic disorders can be absent in patients with late-
onset partial lipodystrophy. Furthermore, acanthosis 
Fig. 1 Progressive facial lipoatrophy with loss of buccal fat pads
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nigricans, hirsutism and signs of virilization are very 
unusual [13].
Mutations in several genes have been found in patients 
with inherited lipodystrophies, including mutations in 
LMNA, PPARG, AKT2 and ZMPSTE24 in partial lipod-
ystrophy [18], and mutations in AGPAT2, BSCL2, CAV1 
and PTRF in congenital total lipodystrophy [19–21]. 
However, the molecular pathogenesis of APL has not 
been clearly established. In 2006, Hegele proposed that 
LMNB2 could be a mutation responsible for APL. In four 
out of nine patients he found three new rare LMNB2 
mutations, by using candidate gene sequencing. He con-
cluded that not all subjects with APL had LMNB2 muta-
tions and also found a few carrier mutations among 
healthy controls. Therefore, it seems that APL behaves 
like a complex trait, in which a susceptibility allele 
requires the presence of additional factors to trigger the 
expression of the disease [22]. A family history is usu-
ally absent, and a broad set of autoimmune diseases is 
often associated [17]: membranoproliferative glomeru-
lonephritis, hypocomplementemia, systemic lupus ery-
thematosus, dermatomyositis and localized scleroderma 
[23–25]. Occasional functional anomalies, such as deaf-
ness, epilepsy, and mental retardation can also be associ-
ated with the condition [26].
Therapeutic approaches for APL consist of improving 
esthetic appearance with plastic surgery and the manage-
ment of additional systemic disorders. The main goal of 
cosmetic surgical procedures is to minimize the psycho-
logical discomfort that impairs the patient’s quality of life. 
Metabolic complications are not usually a main problem, 
however they still have to be screened and treated when 
they exist. A hypolipidic diet plan and regular exercise 
were advised, and medication will be offered when nec-
essary. Thiazolidinediones stimulate growth and differ-
entiation of adipocytes and seem to be effective in some 
heterogeneous forms of lipodystrophy. In 2003, Walker 
et al [27] reported increases of fat in buccal and subcuta-
neous abdominal adipose tissue in a 20-year-old woman 
with APL after 7 months of rosiglitazone therapy. Unfor-
tunately, this may exacerbate the fat accumulation in 
non-affected regions. Recently, metreleptin, a recombi-
nant analogue of human leptin, has been approved for the 
treatment of metabolic derangements of lipodystrophy. 
Metreleptin replaces the leptin deficiency, thus improv-
ing insulin resistance, hyperglycemia, dyslipidemia, and 
hepatic steatosis. Acquired partial lipodystrophy has less 
low leptin levels, and less metabolic derangements, and 
therefore metreleptin has lower efficacy [28]. The prog-
nosis of Barraquer–Simons syndrome is mainly depend-
ent on renal disease. A few patients have required renal 
transplantation for end-stage renal disease related to glo-
merulonephritis [29, 30].
Conclusions
Barraquer–Simons syndrome is an extremely rare disor-
der with important clinical consequences and psychoso-
cial effects. The authors underline the importance of the 
identification and the periodic assessment of patients 
with APL. Close long-term follow-up is required to iden-
tify metabolic disturbances, potentially life-threatening 
renal problems, and other associated diseases.
Consent
Written informed consent was obtained from the patient 
for publication of this Case Report and any accompany-
ing images.
Fig. 2 Subcutaneous adipose tissue preserved in the lower abdo-
men and thighs
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